Pradeep Natarajan, MD, MMSc

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Bristol Myers Squibb
    Topic:
    CVD drug development
    Date added:
    12/05/2025
    Date updated:
    12/05/2025
    Relationship end date:
    12/01/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Eli Lilly & Co
    Topic:
    CVD drug development
    Date added:
    12/05/2025
    Date updated:
    12/05/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Esperion Therapeutics
    Topic:
    CVD drug development
    Date added:
    12/05/2025
    Date updated:
    12/05/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Foresite Capital
    Topic:
    CVD drug development
    Date added:
    12/05/2025
    Date updated:
    12/05/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Foresite Labs
    Topic:
    CVD drug development
    Date added:
    12/05/2025
    Date updated:
    12/05/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Genentech / Roche
    Topic:
    CVD drug development
    Date added:
    12/05/2025
    Date updated:
    12/05/2025
    Relationship end date:
    12/01/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Incyte
    Topic:
    CVD drug development
    Date added:
    12/05/2025
    Date updated:
    12/05/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Merck
    Topic:
    CVD drug development
    Date added:
    12/05/2025
    Date updated:
    12/05/2025
    Relationship end date:
    12/01/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Novartis
    Topic:
    CVD drug development
    Date added:
    12/05/2025
    Date updated:
    12/05/2025
    Relationship end date:
    12/01/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Novo Nordisk
    Topic:
    CVD drug development
    Date added:
    12/05/2025
    Date updated:
    12/05/2025
    Relationship end date:
    12/01/2025

Pages

Return to 2025 Inova Fairfax Medicine Grand Rounds 12/09/2025